IPG7236 for Tolerability

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Tolerability+2 MoreIPG7236 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, IPG7236, to see if it is safe and effective in treating patients with advanced solid tumors. The trial will have two parts, with the first part testing different doses of the drug to see what is safe and tolerable, and the second part expanding to include more patients to further test the drug's effectiveness.

Eligible Conditions
  • Tolerability
  • Pharmacokinetics
  • Safety Concerns

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Keytruda
1
Dostarlimab
1
GSK3745417

Study Objectives

4 Primary · 9 Secondary · Reporting Duration: up to 1 year(anticipated)

Up to 33 days
Apparent terminal phase half-life (t1/2)
Area under the serum concentration-infinity curve AUC[0-infinity]
Area under the serum concentration-time curve (AUC[0-t]
Maximum plasma concentration（Cmax）
Maximum tolerated dose (MTD）
Occurrence of all adverse events
Phase II dose (RP2D)
Time to Cmax (tmax)
up to 1 year(anticipated)
Disease Control Rate(DCR)
Duration of response (DoR)
Overall Response Rate (ORR)
Progression-free survival (PFS)
Time to Progression(TTP)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Keytruda
1
Dostarlimab
1
GSK3745417

Trial Design

6 Treatment Groups

Cohort 2
1 of 6
Cohort 1
1 of 6
Cohort 3
1 of 6
Cohort 6
1 of 6
Cohort 5
1 of 6
Cohort 4
1 of 6

Experimental Treatment

196 Total Participants · 6 Treatment Groups

Primary Treatment: IPG7236 · No Placebo Group · Phase 1

Cohort 2
Drug
Experimental Group · 1 Intervention: IPG7236 · Intervention Types: Drug
Cohort 1
Drug
Experimental Group · 1 Intervention: IPG7236 · Intervention Types: Drug
Cohort 3
Drug
Experimental Group · 1 Intervention: IPG7236 · Intervention Types: Drug
Cohort 6
Drug
Experimental Group · 1 Intervention: IPG7236 · Intervention Types: Drug
Cohort 5
Drug
Experimental Group · 1 Intervention: IPG7236 · Intervention Types: Drug
Cohort 4
Drug
Experimental Group · 1 Intervention: IPG7236 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year(anticipated)

Who is running the clinical trial?

Nanjing Immunophage Biotech Co., LtdLead Sponsor
2 Previous Clinical Trials
132 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a solid malignancy that is either metastatic or unresectable.
You have head and neck cancer.
The following tumor types are tentatively planned for expansion
Subjects must have failed established standard medical anti-cancer therapies for a given tumor type or have been intolerant to such therapy, or in the opinion of the Investigator have been considered ineligible for standard therapies on medical grounds.
You must give informed consent prior to participating in a study.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top